Clinical Trial Update: Study of Olmesartan Medoxomil (CS-866) in Patients With Chronic Glomerulonephritis or Diabetic Nephropathy [Phase 2]

View source ↗

Summary

A Phase 2 study of olmesartan medoxomil (CS-866) in patients with chronic glomerulonephritis or diabetic nephropathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy
• Glomerulonephritis

Drugs mentioned

• Olmesartan Medoxomil (CS-866) (olmesartan medoxomil)

Snippet

Sponsor: Daiichi Sankyo Co., Ltd. | Conditions: Chronic Glomerulonephritis, Diabetic Nephropathy | Phase 2 | Status: COMPLETED